NASDAQ:VRNA - VERONA PHARMA P/S Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$15.76 -0.20 (-1.25 %)
(As of 06/20/2018 05:47 AM ET)
Previous Close$15.97
Today's Range$15.70 - $16.06
52-Week Range$10.44 - $25.55
Volume2,000 shs
Average Volume9,852 shs
Market Capitalization$211.35 million
P/E Ratio-6.52
Dividend YieldN/A
Beta-3.13
VERONA PHARMA P/S logoVerona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Receive VRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VRNA
CUSIPN/A
Phone44-20-3283-4200

Debt

Debt-to-Equity RatioN/A
Current Ratio4.94
Quick Ratio4.94

Price-To-Earnings

Trailing P/E Ratio-6.52
Forward P/E Ratio-4.02
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$7.84 per share
Price / Book2.01

Profitability

EPS (Most Recent Fiscal Year)($2.41)
Net Income$-26,410,000.00
Net MarginsN/A
Return on Equity-42.87%
Return on Assets-37.51%

Miscellaneous

Employees15
Outstanding Shares13,130,000

VERONA PHARMA P/S (NASDAQ:VRNA) Frequently Asked Questions

What is VERONA PHARMA P/S's stock symbol?

VERONA PHARMA P/S trades on the NASDAQ under the ticker symbol "VRNA."

How were VERONA PHARMA P/S's earnings last quarter?

VERONA PHARMA P/S (NASDAQ:VRNA) posted its quarterly earnings results on Tuesday, May, 8th. The company reported ($1.61) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.63) by $0.98. View VERONA PHARMA P/S's Earnings History.

When is VERONA PHARMA P/S's next earnings date?

VERONA PHARMA P/S is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for VERONA PHARMA P/S.

What price target have analysts set for VRNA?

4 brokers have issued 1-year price objectives for VERONA PHARMA P/S's stock. Their predictions range from $25.00 to $55.00. On average, they anticipate VERONA PHARMA P/S's stock price to reach $36.75 in the next twelve months. View Analyst Ratings for VERONA PHARMA P/S.

Who are some of VERONA PHARMA P/S's key competitors?

Who are VERONA PHARMA P/S's key executives?

VERONA PHARMA P/S's management team includes the folowing people:
  • Dr. Jan-Anders Karlsson, Chief Exec. Officer & Exec. Director (Age 63)
  • Mr. Piers John Morgan MA, ACA, Chief Financial Officer (Age 52)
  • Ms. Claire Louise Poll, Legal Counsel (Age 51)
  • Dr. Peter Spargo Ph.D., Sr. VP of CMC (Age 56)
  • Dr. Kenneth Newman, Chief Medical Officer (Age 60)

When did VERONA PHARMA P/S IPO?

(VRNA) raised $61 million in an IPO on Thursday, April 27th 2017. The company issued 4,500,000 shares at a price of $13.49 per share. Jefferies and Stifel acted as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.

Has VERONA PHARMA P/S been receiving favorable news coverage?

Media headlines about VRNA stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. VERONA PHARMA P/S earned a news sentiment score of 0.12 on Accern's scale. They also gave media headlines about the company an impact score of 45.99 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are VERONA PHARMA P/S's major shareholders?

VERONA PHARMA P/S's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Foresite Capital Management III LLC (4.31%). View Institutional Ownership Trends for VERONA PHARMA P/S.

Which institutional investors are buying VERONA PHARMA P/S stock?

VRNA stock was purchased by a variety of institutional investors in the last quarter, including Foresite Capital Management III LLC. View Insider Buying and Selling for VERONA PHARMA P/S.

How do I buy shares of VERONA PHARMA P/S?

Shares of VRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is VERONA PHARMA P/S's stock price today?

One share of VRNA stock can currently be purchased for approximately $15.76.

How big of a company is VERONA PHARMA P/S?

VERONA PHARMA P/S has a market capitalization of $211.35 million. The company earns $-26,410,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. VERONA PHARMA P/S employs 15 workers across the globe.

How can I contact VERONA PHARMA P/S?

VERONA PHARMA P/S's mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The company can be reached via phone at 44-20-3283-4200 or via email at [email protected]


MarketBeat Community Rating for VERONA PHARMA P/S (VRNA)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  109 (Vote Outperform)
Underperform Votes:  70 (Vote Underperform)
Total Votes:  179
MarketBeat's community ratings are surveys of what our community members think about VERONA PHARMA P/S and other stocks. Vote "Outperform" if you believe VRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.